Login
$OTLC
$0.03 -$0.00 (1.91%) Close

Ownership

13F as of Q2 2026 · 457.5M shares outstanding

Who owns OTLC?

By type of holder
Institutions 0.0% Insiders 31.0% Everyone else 69.0%
Concentration Top 2 holders own 31.0%
Trieu Vuong 30.9% · Shah Amit B. 0.1%
Institutional ownership
0.0%
0.0 pts vs last qtr
Institutional holders
0
0 vs last qtr
Net shares bought
0
by institutions in Q2 2026
New / sold out
0 / 0
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

No 13F manager has reported this stock in the last 8 quarters.

Biggest buyers in Q2 2026

None.

Biggest sellers in Q2 2026

None.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Oncotelic Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2021–FY2025
+39.3%
+8.64% a year
Each share's claim on the business
−28.2%
shrank without buying or selling a share
Spent on buybacks vs paid in stock
— vs $4.04M
over 5 fiscal years
Diluted shares, split-adjusted
294.0M377.9M461.9M2021: 303.1M shares'212022: 457.3M shares'222023: 396.2M shares'232024: 404.4M shares'242025: 422.2M shares'25
Buybacks Stock-based comp
$0$1.2M$2.4M2021 buybacks: $02021 stock comp: $763.3K'212022 buybacks: $02022 stock comp: $902.1K'222023 buybacks: $02023 stock comp: $0'232024 buybacks: $02024 stock comp: $0'242025 buybacks: $02025 stock comp: $2.4M'25

How patient are the owners?

No 13F manager reports holding OTLC.

Super Investors

Investment managers reporting OTLC on Form 13F
No 13F manager reports holding OTLC yet.

Institutional Funds

Mutual funds and ETFs reporting OTLC on Form N-PORT; together they hold 0.0% of the company
EM
USAA Mutual Funds Trust
Position value
$7.59K
% of company
0.01%
% of the fund
0.00%
As of
September 30, 2021

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
TV
Trieu Vuong
Insider
Shares
141.4M
% of company
30.91%
Change vs last qtr
—
Held since
—
SA
Shah Amit B.
Insider
Shares
378.8K
% of company
0.08%
Change vs last qtr
—
Held since
—

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support